Iodopol

Sodium Iodide I-131, the active ingredient in Iodopol, is a radioactive iodine presented as an oral preparation for oral use. It treats thyroid disease such as thyroid cancer, hyperthyroidism, and is employed for thyroid tissue ablation and diagnostic imaging of the thyroid.

GNH USA supplies Iodopol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iodopol (Sodium Iodide I-131) is a radioactive iodine used in the management of thyroid disorders.

- Thyroid cancer: provides targeted radiation to destroy residual thyroid tissue after surgery. - Hyperthyroidism: ablates over‑active thyroid tissue to reduce hormone production. - Thyroid tissue ablation: prepares patients for subsequent radioactive iodine therapy or facilitates diagnostic imaging. - Diagnostic imaging of the thyroid: enables scintigraphic evaluation of thyroid function and anatomy.

Iodopol may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Dry mouth or altered taste - Neck pain or tenderness - Transient hypothyroidism - Mild leukopenia or reduced blood counts - Fatigue or mild headache

Serious or Rare Side Effects: - Severe hypothyroidism requiring hormone replacement - Radiation thyroiditis with painful swelling - Bone marrow suppression leading to pancytopenia - Secondary malignancies such as leukemia - Allergic reactions including rash or anaphylaxis - Pulmonary fibrosis in rare cases

Before using Iodopol, consider the following safety measures.

- Pregnancy: avoid unless clearly indicated, as fetal radiation exposure can be harmful. - Breastfeeding: discontinue nursing or choose an alternative, because iodine can be secreted in milk. - Radiation safety: limit close contact with pregnant women and young children for several days after administration. - Thyroid function monitoring: perform baseline and periodic thyroid hormone tests. - Hematologic monitoring: check complete blood counts before and after treatment. - Interference with other iodine‑containing drugs: suspend antithyroid medications and high‑dose iodinated contrast agents as advised. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Iodopol can interact with several medicines and substances.

Major Interactions (Avoid): - Antithyroid drugs (e.g., propylthiouracil, methimazole) markedly reduce iodine uptake. - Lithium therapy diminishes thyroid iodine accumulation. - High‑dose iodinated contrast agents administered shortly before or after Iodopol can interfere with therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Levothyroxine may require dose adjustment after Iodopol therapy. - Myelosuppressive chemotherapy agents can compound bone‑marrow toxicity. - Certain radiopharmaceuticals used for other diagnostic purposes may increase cumulative radiation exposure.